AleemA, Akbar SamadAB, SlenkerAK: Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). StatPearls Publishing LLC. Treasure Island, FL, USA, 2022.
2.
MykytynAZ, RissmannM, KokA, et al.Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. Sci Immunol. 2022; 7:eabq4450. doi: 4410.1126/sciimmunol.abq4450. Epub 2022 Sep 4423.
3.
van der StratenK, GuerraD, van GilsMJ, et al.Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. Immunity. 2022; 55:1725–1731.e1724. doi: 1710.1016/j.immuni.2022.1707.1018. Epub 2022 Aug 1725.
4.
GaeblerC, WangZ, LorenziJCC, et al.Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591:639–644.
5.
WheatleyAK, FoxA, TanHX, et al.Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. 2021; 42:956–959.
6.
KohlerH, NaraP: A Novel Hypothesis for Original Antigenic Sin in the Severe Disease of SARS-CoV-2 Infection. Monoclon Antib Immunodiagn Immunother. 2020; 39:107–111.
7.
BeklizM, AdeaK, VetterP, et al.Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat Commun. 2022; 13:3840. doi: 3810.1038/s41467-41022-31556-41461.
8.
YuY, EspositoD, KangZ, et al.mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Sci Rep. 2022; 12:2628. doi: 2610.1038/s41598-41022-06629-41592.
9.
DaiL, ZhengT, XuK, et al.A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020; 182:722–733.e711. doi: 710.1016/j.cell.2020.1006.1035. Epub 2020 Jun 1028.
10.
CorbettKS, EdwardsDK, LeistSR, et al.SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586:567–571. doi: 510.1038/s41586-41020-42622-41580. Epub 42020 Aug 41585.
11.
NanduriS, PilishviliT, DeradoG, et al.Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70:1163–1166. doi: 1110.15585/mmwr.mm17034e15583.
12.
HauserBM, SangeslandM, LamEC, et al.Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. Front Immunol. 2022; 13:902260.:10.3389/fimmu.2022.902260. eCollection 902022.
13.
MinL, SunQ: Antibodies and Vaccines Target RBD of SARS-CoV-2. Front Mol Biosci. 2021; 8:671633.:10.3389/fmolb.2021.671633. eCollection 672021.
14.
BarnesCO, JetteCA, AbernathyME, et al.SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020; 588:682–687. doi: 610.1038/s41586-41020-42852-41581. Epub 42020 Oct 41512.
15.
WecAZ, WrappD, HerbertAS, et al.Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020; 369:731–736. doi: 710.1126/science.abc7424. Epub 2020 Jun 1115.
16.
SapkotaB, SaudB, ShresthaR, et al.Heterologous prime-boost strategies for COVID-19 vaccines. J Travel Med. 2022; 29:taab191. doi: 110.1093/jtm/taab1191.
17.
LiuX, ShawRH, StuartASV, et al.Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021; 398:856–869. doi: 810.1016/S0140-6736(1021)01694-01699. Epub 02021 Aug 01696.
18.
ShawRH, StuartA, GreenlandM, et al.Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021; 397:2043–2046. doi: 2010.1016/S0140-6736(2021)01115-01116. Epub 02021 May 01112.
